BCG, ChadOx/MVA 5Ag
Candidate Overview
ChAdOx1.5Ag is a recombinant, replication deficient chimpanzee adenovirus, expressing the four antigens of the mycobacterium Esx-5a system (PPE15, PE8, EsxI, EsxJ), along with Ag85A. In mice, ChAdOx1.5Ag improved the efficacy of BCG in the lung and spleen, and a further boost with MVA.5Ag further improved efficacy in the spleen. ChAdOx1.5Ag/MVA.5Ag was also promising in non-human primates.
Sponsor / Lead Developer: University of Oxford
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB disease
Target Population(s): Adolescents and Adults
Target Route of Administration: Aerosol and Intramuscular
Immune tissue localization: Blood, Lung, and Spleen
Immunological responses: T-cell
Preclinical Animal Models: Mouse and Nonhuman primate
Intended to elicit trained immunity: No
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ TNF-α IL-17 |
|
| Preferential immune tissue localization | Lung Spleen Blood |
|
| Trained immunity | No | |